Goosebumps, I believe the claim was that Leronlimab

Quote:

VANCOUVER, Washington, July 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company" , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential clinical indications for HIV, COVID-19, cancer, GvHD and NASH announced today the results from a preclinical macaque study evaluating leronlimab as pre-exposure prophylaxis (PrEP) to prevent sexual HIV transmission. The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques. These results were presented today in an oral presentation titled "CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition" at the 23rd International AIDS Conference (AIDS 2020).

Quote:

In the absence of a prophylactic vaccine, the use of antiretroviral medications as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic. Unfortunately, negative side effects, viral resistance, and regimen adherence severely limit PrEP efficacy. Therefore, the development of new, highly effective, and long-acting PrEP modalities with high patient uptake is urgently needed. The scientific premise for leronlimab-based PrEP is founded on the long-standing observation that CCR5-deficient individuals are extremely resistant to HIV infection. The results presented here demonstrate that leronlimab treatment is able to prevent sexual transmission of HIV. Given leronlimab's excellent safety profile, this finding paves the way for a new, patient-friendly PrEP regimen.

Quote:

In the whole of the U.S. drug pricing debate, few drugs have drawn more controversy in recent months than Truvada, the HIV prevention pill from Gilead Sciences (ticker GILD). It costs around $20,000 a year, and it was the subject of a fiery Congressional hearing earlier this year.

Quote:

Yet there’s still a huge market opportunity in HIV prevention pills, according to new reports out Friday morning from Citi Research. They argue that the U.S. market for HIV prevention drugs, called PrEP, will more than double to $5.5 billion by 2030.